Real-world treatments and outcomes in intermediate liver cancer
Part of Cancer clinical trials.
This study looks at how people with intermediate-stage liver cancer are actually treated in real life and how long they live. By joining, you help doctors understand which treatments work best for people like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been diagnosed with hepatocellular carcinoma, the most common type of liver cancer, usually confirmed by imaging or a biopsy.
- Your cancer must be classified as intermediate stage (often called BCLC stage B) when you start your first treatment.
- Your liver function must be well enough — your doctor would rate it as Child-Pugh A or B.
- You should be able to care for yourself and be up and about more than half of the day (ECOG score 0 or 1).
- You cannot have had prior curative treatments like surgery to remove the tumor, a liver transplant, or ablation to destroy the tumor, and your cancer must not be a mixed type (HCC-cholangiocarcinoma).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people with advanced liver cancer that cannot be treated with surgery. It aims to gather information about the disease and how it is managed, which could help improve future care.
This study tracks how bile duct and liver cancers change during treatment, to help doctors find the best therapies for patients. It is for people who are newly diagnosed or starting a new treatment.
This study compares two treatment approaches for advanced liver cancer that has spread within the liver but not to other parts of the body. Both treatments combine chemotherapy delivered directly to the liver with immunotherapy drugs to help your immune system fight the cancer.
This trial uses a computer model to predict if your liver cancer might come back aggressively after surgery. If you are at high risk, you may receive additional treatment before surgery to lower that risk.
This study is testing whether combining targeted therapy with immunotherapy (or using two immunotherapies together) can help people with liver cancer that cannot be surgically removed. The goal is to understand how well these treatments work and how they affect biomarkers (signals in your body that show treatment response).
This study reviews medical records of people diagnosed with hepatocellular carcinoma (liver cancer) between 2015 and 2023 to better understand how the disease progresses and how different treatments work. Your information helps researchers learn what care approaches work best for future patients.
Hear when a new BCLC Stage B Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.